By Sabela Ojea
Ulta Beauty on Thursday posted better-than-expected sales in the third quarter and raised the lower end of its sales and profit outlook for the year. Shares of the specialty beauty retailer climbed 12%, to $477.70, in after-hours trading.
UiPath said revenue and annual recurring revenue surged more than expected in the fiscal third quarter. Shares of the automation software company rose 12%, to $22.13, in after-hours trading.
Polar Power said it is planning to sell stock and/or warrants in an underwritten public offering. Shares of the company dropped 21%, to 65 cents, in after-hours trading.
Biora Therapeutics’ investigational new drug application for moderate to severe ulcerative colitis treatment BT-600 was cleared by the Food and Drug Administration. Shares of the company surged 65%, to $2.05, in after-hours trading.
Write to Sabela Ojea at [email protected]
Read the full article here